ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Kidney Cancer

Kidney Cancer

The combination of the novel histone deacetylase inhibitor entinostat and high-dose interleukin-2 yielded a promising response rate in patients with metastatic renal cell carcinoma.

A new study has confirmed the safety and efficacy of pazopanib in a real-world setting of patients with metastatic renal cell carcinoma (mRCC) and validates the International Metastatic Renal Cell Carcinoma Database (IMDC) prognostic model in this patient population.

Administering pharmacological prophylaxis against venous thromboembolism (VTE) did not decrease the occurrence of VTE in patients treated with robotic partial nephrectomy, and it did not increase the rate of hemorrhagic events.

The FDA has approved the anti–PD-1 immunotherapy nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma.

A 42-year-old man presented with increasing right hip pain that limited his ability to walk. Magnetic resonance imaging (MRI) revealed a right lytic acetabular lesion. Further work-up included a computed tomography (CT) scan, which revealed an 8-cm left kidney tumor.

A new study suggests that certain mutagens formed during the cooking of meat are linked to a risk of renal cell carcinoma (RCC).

Patients with renal cell carcinoma whose disease progressed after previous VEGF therapy saw increased delays in disease progression when treated with lenvatinib.

Pages

Subscribe to Kidney Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.